Literature DB >> 23641752

Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.

Jodi Lestner1, William W Hope.   

Abstract

INTRODUCTION: Fungal infections are a major source of global morbidity and mortality. Itraconazole is a triazole antifungal agent that is widely used for the prevention and treatment of fungal infection. While newer antifungal agents are now available, itraconazole is an orally bioavailable agent with broad-spectrum antifungal activity. Itraconazole remains a useful drug for the management of allergic and invasive mycoses worldwide. AREAS COVERED: This article provides a summary of the pharmacokinetics, pharmacodynamics and clinical uses of itraconazole. Additionally, the authors summarise the safety and recently described toxicodynamics and discuss the value of therapeutic drug monitoring (TDM) with itraconazole. The following search criteria were constructed in order to identify relevant literature using PubMed and Ovid-MEDLINE: itraconazole, triazole, pharmacokinetics, pharmacodynamics, toxicodynamics and TDM. Relevant abstracts and articles identified from reviewing secondary citations were additionally retrieved and included if relevant. EXPERT OPINION: Itraconazole remains an important agent in the prevention and treatment of fungal infection. Itraconazole has a broad-spectrum of activity and is available in both an intravenous and oral form making long-term use in chronic mycoses practical. Itraconazole is widely used for the treatment of endemic fungal infections. Pharmacokinetic variability and clinically important drug interactions make TDM of itraconazole an important consideration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23641752     DOI: 10.1517/17425255.2013.794785

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  30 in total

Review 1.  Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

Authors:  David J Greenblatt; Jerold S Harmatz
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

2.  Population in vitro-in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole.

Authors:  Ahmad Y Abuhelwa; Stuart Mudge; Richard N Upton; David J R Foster
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-11-17       Impact factor: 2.745

Review 3.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

Authors:  H Ruth Ashbee; Rosemary A Barnes; Elizabeth M Johnson; Malcolm D Richardson; Rebecca Gorton; William W Hope
Journal:  J Antimicrob Chemother       Date:  2013-12-29       Impact factor: 5.790

4.  Bioavailability of Single-Dose SUBA-Itraconazole Compared to Conventional Itraconazole under Fasted and Fed Conditions.

Authors:  Adriana M Rauseo; Patrick Mazi; Phoebe Lewis; Bruce Burnett; Stuart Mudge; Andrej Spec
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

5.  Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs.

Authors:  Xuezhi Yin; Linda Sharon Daintree; Sheng Ding; Daniel Mark Ledger; Bing Wang; Wenwen Zhao; Jianping Qi; Wei Wu; Jiansheng Han
Journal:  Drug Des Devel Ther       Date:  2015-05-28       Impact factor: 4.162

6.  Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.

Authors:  Pan Pantziarka; Vidula Sukhatme; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2015-04-15

Review 7.  Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy.

Authors:  Pierre-Régis Burgel; André Paugam; Dominique Hubert; Clémence Martin
Journal:  Infect Drug Resist       Date:  2016-09-20       Impact factor: 4.003

8.  Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.

Authors:  Katharine E Stott; Thuy Le; Thu Nguyen; Sarah Whalley; Jennifer Unsworth; Vo Trieu Ly; Ruwanthi Kolamunnage-Dona; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

9.  Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein.

Authors:  Jeroen R P M Strating; Lonneke van der Linden; Lucian Albulescu; Joëlle Bigay; Minetaro Arita; Leen Delang; Pieter Leyssen; Hilde M van der Schaar; Kjerstin H W Lanke; Hendrik Jan Thibaut; Rachel Ulferts; Guillaume Drin; Nina Schlinck; Richard W Wubbolts; Navdar Sever; Sarah A Head; Jun O Liu; Philip A Beachy; Maria A De Matteis; Matthew D Shair; Vesa M Olkkonen; Johan Neyts; Frank J M van Kuppeveld
Journal:  Cell Rep       Date:  2015-01-29       Impact factor: 9.423

10.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.